High activity rhenium-186 hydroxyethylidene diphosphonate (HEDP) with autologous peripheral blood stem cell (PBSC) transplant: A novel treatment strategy in hormone refractory prostate cancer metastatic to bone.

Joe O'Sullivan; A.R. Norman; V.R. McCready; G. Flux; G. Cook; B. Johnson; J. Treleaven; D.P. Dearnaley

High activity rhenium-186 hydroxyethylidene diphosphonate (HEDP) with autologous peripheral blood stem cell (PBSC) transplant: A novel treatment strategy in hormone refractory prostate cancer metastatic to bone.

Joe O'Sullivan, A.R. Norman, V.R. McCready, G. Flux, G. Cook, B. Johnson, J. Treleaven, D.P. Dearnaley

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	397S-397S
Journal	Journal of Clinical Oncology
Volume	22
Publication status	Published - 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

O'Sullivan, J., Norman, A. R., McCready, V. R., Flux, G., Cook, G., Johnson, B., Treleaven, J., & Dearnaley, D. P. (2004). High activity rhenium-186 hydroxyethylidene diphosphonate (HEDP) with autologous peripheral blood stem cell (PBSC) transplant: A novel treatment strategy in hormone refractory prostate cancer metastatic to bone. Journal of Clinical Oncology, 22, 397S-397S.

@article{d629981919b842549bd1cc929cddeb6b,

title = "High activity rhenium-186 hydroxyethylidene diphosphonate (HEDP) with autologous peripheral blood stem cell (PBSC) transplant: A novel treatment strategy in hormone refractory prostate cancer metastatic to bone.",

author = "Joe O'Sullivan and A.R. Norman and V.R. McCready and G. Flux and G. Cook and B. Johnson and J. Treleaven and D.P. Dearnaley",

year = "2004",

language = "English",

volume = "22",

pages = "397S--397S",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

}

O'Sullivan, J, Norman, AR, McCready, VR, Flux, G, Cook, G, Johnson, B, Treleaven, J & Dearnaley, DP 2004, 'High activity rhenium-186 hydroxyethylidene diphosphonate (HEDP) with autologous peripheral blood stem cell (PBSC) transplant: A novel treatment strategy in hormone refractory prostate cancer metastatic to bone.', Journal of Clinical Oncology, vol. 22, pp. 397S-397S.

High activity rhenium-186 hydroxyethylidene diphosphonate (HEDP) with autologous peripheral blood stem cell (PBSC) transplant: A novel treatment strategy in hormone refractory prostate cancer metastatic to bone. / O'Sullivan, Joe; Norman, A.R.; McCready, V.R. et al.
In: Journal of Clinical Oncology, Vol. 22, 2004, p. 397S-397S.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - High activity rhenium-186 hydroxyethylidene diphosphonate (HEDP) with autologous peripheral blood stem cell (PBSC) transplant: A novel treatment strategy in hormone refractory prostate cancer metastatic to bone.

AU - O'Sullivan, Joe

AU - Norman, A.R.

AU - McCready, V.R.

AU - Flux, G.

AU - Cook, G.

AU - Johnson, B.

AU - Treleaven, J.

AU - Dearnaley, D.P.

PY - 2004

Y1 - 2004

M3 - Article

SN - 0732-183X

VL - 22

SP - 397S-397S

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -